Physician profile
Su Ah Bae
NPI 1316202666
$1,988.62
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $97.82 · 2021: $378 · 2022: $806 · 2023: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $323.72 | 2021-2023 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $282.31 | 2019-2022 | |
| Novo Nordisk INC | $261.56 | 2019-2023 | Sogroya |
| Lilly USA, LLC | $228.46 | 2019-2023 | Mounjaro |
| Corcept Therapeutics | $112.90 | 2019-2022 | |
| Abbott Laboratories | $92.35 | 2022-2023 | Freestyle Libre 3 |
| Insulet Corporation | $65.53 | 2019-2023 | Omnipod |
| Antares Pharma, INC. | $62.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.42 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.50 | 2022 | |
| Pfizer INC. | $49.78 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $47.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $46.10 | 2022 | |
| Amgen INC. | $43.79 | 2019-2021 | |
| Radius Health, INC. | $35.61 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34.25 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $30.74 | 2019 | |
| Dexcom, INC. | $22.15 | 2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $21.57 | 2023 | Tepezza |
| Amryt Pharma Holdings LTD | $20.55 | 2021 | |
| Medtronic Minimed, INC. | $17.63 | 2019 | |
| Mannkind Corporation | $17.33 | 2022 | |
| Recordati_rare_diseases_inc. | $14.19 | 2022 | |
| Eusa Pharma (US) LLC | $14.19 | 2022 | |
| Halozyme INC | $12.74 | 2023 | |
| Alexion Pharmaceuticals, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su Ah Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.